Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The purpose of this study is to determine the effectiveness of nivolumab adjuvant immunotherapy compared to placebo in adults and pediatric participants after complete resection of Stage IIB/C melanoma with no evidence of disease (NED) who are at high risk for recurrence.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Other protocol defined inclusion/exclusion criteria apply.
Primary purpose
Allocation
Interventional model
Masking
790 participants in 2 patient groups, including a placebo group
There are currently no registered sites for this trial.
Start date
Oct 28, 2019 • 5 years ago
End date
Jun 28, 2022 • 2 years ago
Results posted
ViewJul 27, 2023 • 1 year and 5 months ago
Today
Dec 30, 2024
Lead Sponsor
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal